OncBioMune Pharmaceuticals has signed a Memorandum of Understanding (MOU) with Vitel Laboratorios for the purpose of establishing a Joint Venture (JV), to be named OncBioMune Mexico, to develop and commercialize OncBioMune’s portfolio of innovative cancer therapies in Mexico and Latin America.
Contract Research & Services > Contract Services > News

Moberg Pharma and Cadila Pharmaceuticals have signed an agreement for late-stage development and commercialization of BUPI, a novel lozenge formulation of bupivacaine for pain management in oral mucositis patients.
Contract Research & Services > Contract Services > News

SRI International has been awarded a contract of up to $19.8m from the National Cancer Institute (NCI) PREVENT Cancer Preclinical Drug Development Program to support the development of potential cancer preventive agents or vaccines.
Contract Research & Services > Contract Services > News

AstraZeneca has agreed to sell the European marketing rights for the opioid-induced constipation (OIC) drug Moventig to ProStrakan, a unit of Japanese biopharmaceutical company Kyowa Hakko Kirin.
Contract Research & Services > Contract Services > News